Sarepta fails confirmatory trial for DMD therapy, still eyes label expansion Therapeutics Despite failing to hit the primary endpoint in the Phase III EMBARK study, the company plans to file for a label expansion for its Duchenne muscular dystrophy gene therapy Elevidys. Read more October 31, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/02/FDA-Approves-Third-Sarepta-Treatment-For-Duchenne-Muscular-Dystrophy-BioSpace-2-26-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-10-31 09:15:402023-10-31 09:54:10Sarepta fails confirmatory trial for DMD therapy, still eyes label expansion
